{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:37:50Z","timestamp":1785523070534,"version":"3.56.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40266-026-01318-5","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:32:54Z","timestamp":1785144774000},"page":"675-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Caring for Older Adults with Acute Myeloid Leukemia: Best Practices for Aligning Patient Fitness and Preference with Available Therapies"],"prefix":"10.1007","volume":"43","author":[{"given":"Stephanie","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Wanjiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9310-5773","authenticated-orcid":false,"given":"Daniel R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"6","key":"1318_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000531628","volume":"146","author":"JH Choi","year":"2023","unstructured":"Choi JH, Shukla M, Abdul-Hay M. Acute myeloid leukemia treatment in the elderly: a comprehensive review of the present and future. Acta Haematol. 2023;146(6):431\u201357. https:\/\/doi.org\/10.1159\/000531628.","journal-title":"Acta Haematol"},{"issue":"12","key":"1318_CR2","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"1980","unstructured":"Sasaki K, Ravandi F, Kadia TM, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 1980;127(12):2049\u201361. https:\/\/doi.org\/10.1002\/cncr.33458.","journal-title":"Cancer"},{"issue":"6","key":"1318_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1182\/bloodadvances.2025017934","volume":"10","author":"MA Sekeres","year":"2025","unstructured":"Sekeres MA, Mattison RJ, Artz AS, et al. American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2025;10(6):1897\u2013928. https:\/\/doi.org\/10.1182\/bloodadvances.2025017934.","journal-title":"Blood Adv"},{"issue":"11","key":"1318_CR4","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood.2021013671","volume":"139","author":"GJ Min","year":"2022","unstructured":"Min GJ, Cho BS, Park SS, et al. Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML. Blood. 2022;139(11):1646\u201358. https:\/\/doi.org\/10.1182\/blood.2021013671.","journal-title":"Blood"},{"issue":"21","key":"1318_CR5","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","volume":"121","author":"HD Klepin","year":"2013","unstructured":"Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287\u201394. https:\/\/doi.org\/10.1182\/blood-2012-12-471680.","journal-title":"Blood"},{"issue":"4","key":"1318_CR6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/jamaoncol.2020.6736","volume":"7","author":"MV Garcia","year":"2021","unstructured":"Garcia MV, Agar MR, Soo WK, To T, Phillips JL. Screening tools for identifying older adults with cancer who may benefit from a geriatric assessment: a systematic review. JAMA Oncol. 2021;7(4):616\u201327. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6736.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1318_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf118","volume":"30","author":"R Chen","year":"2025","unstructured":"Chen R, Yang D, Tian M, Xu H, Jin X. The prognostic role of Geriatric 8 in patients with cancer: a meta-analysis and systematic review. Oncologist. 2025;30(6):oyaf118. https:\/\/doi.org\/10.1093\/oncolo\/oyaf118.","journal-title":"Oncologist"},{"issue":"6","key":"1318_CR8","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/S1470-2045(18)30348-6","volume":"19","author":"E Soto-Perez-de-Celis","year":"2018","unstructured":"Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018;19(6):e305\u201316. https:\/\/doi.org\/10.1016\/S1470-2045(18)30348-6.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1318_CR9","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1016\/S2352-3026(21)00241-6","volume":"8","author":"R Cordoba","year":"2021","unstructured":"Cordoba R, Eyre TA, Klepin HD, Wildes TM, Goede V. A comprehensive approach to therapy of haematological malignancies in older patients. Lancet Haematol. 2021;8(11):e840\u201352. https:\/\/doi.org\/10.1016\/S2352-3026(21)00241-6.","journal-title":"Lancet Haematol."},{"issue":"6","key":"1318_CR10","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/imj.70086","volume":"55","author":"B Shaw","year":"2025","unstructured":"Shaw B, Ling VYM, Hubbard RE, et al. Frailty and geriatric assessments in older patients diagnosed with acute myeloid leukaemia: an Australasian Leukaemia and Lymphoma Group consensus statement. Intern Med J. 2025;55(6):1013\u20138. https:\/\/doi.org\/10.1111\/imj.70086.","journal-title":"Intern Med J"},{"issue":"1","key":"1318_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-022-03024-4","volume":"22","author":"G Sum","year":"2022","unstructured":"Sum G, Nicholas SO, Nai ZL, Ding YY, Tan WS. Health outcomes and implementation barriers and facilitators of comprehensive geriatric assessment in community settings: a systematic integrative review [PROSPERO registration no.: CRD42021229953]. BMC Geriatr. 2022;22(1):379. https:\/\/doi.org\/10.1186\/s12877-022-03024-4.","journal-title":"BMC Geriatr"},{"issue":"26","key":"1318_CR12","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","volume":"41","author":"W Dale","year":"2023","unstructured":"Dale W, Klepin HD, Williams GR, et al. Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update. J Clin Oncol. 2023;41(26):4293\u2013312. https:\/\/doi.org\/10.1200\/JCO.23.00933.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1318_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020597","volume":"8","author":"E Ferrat","year":"2018","unstructured":"Ferrat E, Bastuji-Garin S, Paillaud E, et al. Efficacy of nurse-led and general practitioner-led comprehensive geriatric assessment in primary care: protocol of a pragmatic three-arm cluster randomised controlled trial (CEpiA study). BMJ Open. 2018;8(4):e020597. https:\/\/doi.org\/10.1136\/bmjopen-2017-020597.","journal-title":"BMJ Open"},{"issue":"6","key":"1318_CR14","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1111\/jgs.19402","volume":"73","author":"C Hayes","year":"2025","unstructured":"Hayes C, Yigezu A, Dillon S, et al. Home-based comprehensive geriatric assessment for community-dwelling, at-risk, frail older adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2025;73(6):1929\u201339. https:\/\/doi.org\/10.1111\/jgs.19402.","journal-title":"J Am Geriatr Soc"},{"issue":"10314","key":"1318_CR15","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","volume":"398","author":"SG Mohile","year":"2021","unstructured":"Mohile SG, Mohamed MR, Xu H, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet. 2021;398(10314):1894\u2013904. https:\/\/doi.org\/10.1016\/S0140-6736(21)01789-X.","journal-title":"Lancet"},{"key":"1318_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101224","volume":"68","author":"LS Williams","year":"2024","unstructured":"Williams LS, Nagaradona T, Nalamalapu P, Lai C. Breaking down frailty: assessing vulnerability in acute myeloid leukemia. Blood Rev. 2024;68:101224. https:\/\/doi.org\/10.1016\/j.blre.2024.101224.","journal-title":"Blood Rev"},{"issue":"4","key":"1318_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041002","volume":"15","author":"S Aydin","year":"2023","unstructured":"Aydin S, Passera R, Cerrano M, et al. Combining the HCT-CI, G8, and AML-score for fitness evaluation of elderly patients with acute myeloid leukemia: a single center analysis. Cancers. 2023;15(4):1002. https:\/\/doi.org\/10.3390\/cancers15041002.","journal-title":"Cancers"},{"issue":"16_Suppl.","key":"1318_CR18","doi-asserted-by":"publisher","first-page":"11013","DOI":"10.1200\/JCO.2025.43.16_suppl.11013","volume":"43","author":"DR Richardson","year":"2025","unstructured":"Richardson DR, Wang Y, Flannery MA, et al. Treatment preferences between survival and quality of life and their association with clinical outcomes in older adults with advanced cancer. J Clin Oncol. 2025;43(16_Suppl.):11013. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.11013.","journal-title":"J Clin Oncol"},{"key":"1318_CR19","doi-asserted-by":"publisher","unstructured":"Seghers PAL (Nelleke), Wiersma A, Festen S, et al. Patient preferences for treatment outcomes in oncology with a focus on the older patient: a systematic review. Cancers. 2022;14(5):1147. https:\/\/doi.org\/10.3390\/cancers14051147.","DOI":"10.3390\/cancers14051147"},{"issue":"7","key":"1318_CR20","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/pon.5054","volume":"28","author":"A Shrestha","year":"2019","unstructured":"Shrestha A, Martin C, Burton M, Walters S, Collins K, Wyld L. Quality of life versus length of life considerations in cancer patients: a systematic literature review. Psychooncology. 2019;28(7):1367\u201380. https:\/\/doi.org\/10.1002\/pon.5054.","journal-title":"Psychooncology"},{"issue":"5","key":"1318_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101529","volume":"14","author":"M LoCastro","year":"2023","unstructured":"LoCastro M, Wang Y, Sanapala C, et al. Patient preferences, regret, and health-related quality of life among older adults with acute myeloid leukemia: a pilot longitudinal study. J Geriatr Oncol. 2023;14(5):101529. https:\/\/doi.org\/10.1016\/j.jgo.2023.101529.","journal-title":"J Geriatr Oncol"},{"issue":"7","key":"1318_CR22","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/pon.5652","volume":"30","author":"DR Richardson","year":"2021","unstructured":"Richardson DR, Oakes AH, Crossnohere NL, et al. Prioritizing the worries of AML patients: quantifying patient experience using best\u2013worst scaling. Psychooncology. 2021;30(7):1104\u201311. https:\/\/doi.org\/10.1002\/pon.5652.","journal-title":"Psychooncology"},{"issue":"22","key":"1318_CR23","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1200\/JCO.19.02809","volume":"38","author":"C DuMontier","year":"2020","unstructured":"DuMontier C, Loh KP, Bain PA, et al. Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review. J Clin Oncol. 2020;38(22):2558\u201369. https:\/\/doi.org\/10.1200\/JCO.19.02809.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"1318_CR24","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2025-2644","volume":"146","author":"D Richardson","year":"2025","unstructured":"Richardson D, Cole A, Mhina C, et al. Creating a tool for measuring preferences for treating blood cancers in older adults using implementation science. Blood. 2025;146(Suppl. 1):2644. https:\/\/doi.org\/10.1182\/blood-2025-2644.","journal-title":"Blood"},{"issue":"2","key":"1318_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2025.102187","volume":"16","author":"KP Loh","year":"2025","unstructured":"Loh KP, Ng QMR, Mohile SG, et al. Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid leukemia and their caregivers: UR-GOAL 3. J Geriatr Oncol. 2025;16(2):102187. https:\/\/doi.org\/10.1016\/j.jgo.2025.102187.","journal-title":"J Geriatr Oncol"},{"issue":"26","key":"1318_CR26","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684\u201392. https:\/\/doi.org\/10.1200\/JCO.2017.77.6112.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1318_CR27","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8(7):e481\u201391. https:\/\/doi.org\/10.1016\/S2352-3026(21)00134-4.","journal-title":"Lancet Haematol."},{"issue":"8","key":"1318_CR28","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jgo.2020.06.019","volume":"11","author":"T Reljic","year":"2020","unstructured":"Reljic T, Sehovic M, Lancet J, et al. Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: a systematic review and meta-analysis. J Geriatr Oncol. 2020;11(8):1293\u2013308. https:\/\/doi.org\/10.1016\/j.jgo.2020.06.019.","journal-title":"J Geriatr Oncol"},{"key":"1318_CR29","doi-asserted-by":"publisher","unstructured":"Chetasi Talati, Varun C Dhulipala, Mar tine Extermann, et al. Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia. Haematologica. 2020;105(2):398\u2013406. https:\/\/doi.org\/10.3324\/haematol.2018.208637.","DOI":"10.3324\/haematol.2018.208637"},{"issue":"24","key":"1318_CR30","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1182\/blood.2024026004","volume":"145","author":"S Abedin","year":"2025","unstructured":"Abedin S, Uy GL, Michaelis LC. The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment. Blood. 2025;145(24):2840\u20136. https:\/\/doi.org\/10.1182\/blood.2024026004.","journal-title":"Blood"},{"key":"1318_CR31","doi-asserted-by":"publisher","unstructured":"Fathi A, Perl A, Fell G, et al. Results from paradigm: a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. 67th ASH Annual Meeting Abstracts. 2025;146:6. https:\/\/doi.org\/10.1182\/blood-2025-6.","DOI":"10.1182\/blood-2025-6"},{"issue":"8","key":"1318_CR32","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamaoncol.2024.1823","volume":"10","author":"DR Richardson","year":"2024","unstructured":"Richardson DR, Zhou X, Reeder-Hayes K, et al. Home time among older adults with acute myeloid leukemia following chemotherapy. JAMA Oncol. 2024;10(8):1038\u201346. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1823.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1318_CR33","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3324\/haematol.2023.284133","volume":"109","author":"CE Jensen","year":"2024","unstructured":"Jensen CE, Deal AM, Wardell AC, Heiling HM, Beke KE, Richardson DR. Home time among older adults with acute myeloid leukemia by therapy intensity. Haematologica. 2024;109(5):1588\u201392. https:\/\/doi.org\/10.3324\/haematol.2023.284133.","journal-title":"Haematologica"},{"issue":"4","key":"1318_CR34","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3324\/haematol.2022.280728","volume":"108","author":"CE Jensen","year":"2023","unstructured":"Jensen CE, Heiling HM, Beke KE, et al. Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens. Haematologica. 2023;108(4):1006\u201314. https:\/\/doi.org\/10.3324\/haematol.2022.280728.","journal-title":"Haematologica"},{"issue":"4","key":"1318_CR35","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324. https:\/\/doi.org\/10.1002\/ajh.27246.","journal-title":"Am J Hematol"},{"key":"1318_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02730-3","author":"A Venditti","year":"2025","unstructured":"Venditti A, Hou JZ, Fenaux P, et al. Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025. https:\/\/doi.org\/10.1038\/s41375-025-02730-3.","journal-title":"Leukemia"},{"issue":"21","key":"1318_CR37","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169\u201373. https:\/\/doi.org\/10.1182\/blood.2024025409.","journal-title":"Blood"},{"issue":"9","key":"1318_CR38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s11864-025-01351-3","volume":"26","author":"GH Magee","year":"2025","unstructured":"Magee GH, Grunwald MR. Updates on therapy options in fit and unfit patients with newly diagnosed AML. Curr Treat Options Oncol. 2025;26(9):829\u201340. https:\/\/doi.org\/10.1007\/s11864-025-01351-3.","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"1318_CR39","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9):972\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.64.0060.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1318_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3324\/haematol.2024.285879","volume":"110","author":"D Niederwieser","year":"2025","unstructured":"Niederwieser D, Hasenclever D, Berdel WE, et al. Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study. Haematologica. 2025;110(1):68\u201377. https:\/\/doi.org\/10.3324\/haematol.2024.285879.","journal-title":"Haematologica"},{"issue":"11","key":"1318_CR41","doi-asserted-by":"publisher","first-page":"e586","DOI":"10.1016\/S1470-2045(25)00426-7","volume":"26","author":"J Sanz","year":"2025","unstructured":"Sanz J, Bug G, Ciceri F, et al. Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee. Lancet Oncol. 2025;26(11):e586\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(25)00426-7.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1318_CR42","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jgo.2014.04.003","volume":"5","author":"JW Keller","year":"2014","unstructured":"Keller JW, Andreadis C, Damon LE, et al. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014;5(3):238\u201344. https:\/\/doi.org\/10.1016\/j.jgo.2014.04.003.","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"1318_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41408-023-00911-w","volume":"13","author":"NJ Short","year":"2023","unstructured":"Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J. 2023;13(1):142. https:\/\/doi.org\/10.1038\/s41408-023-00911-w.","journal-title":"Blood Cancer J"},{"issue":"18","key":"1318_CR44","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","volume":"6","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Weber D, Krzykalla J, et al. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022;6(18):5345\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2022007223.","journal-title":"Blood Adv"},{"issue":"8","key":"1318_CR45","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","volume":"133","author":"RF Schlenk","year":"2019","unstructured":"Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840\u201351. https:\/\/doi.org\/10.1182\/blood-2018-08-869453.","journal-title":"Blood"},{"issue":"10388","key":"1318_CR46","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(23)00464-6.","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"1318_CR47","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2022-157210","volume":"140","author":"N Short","year":"2022","unstructured":"Short N, DiNardo CD, Daver N, et al. Updated results from a phase I\/II study of the triplet ombination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia. Blood. 2022;140(Suppl. 1):2007\u20139. https:\/\/doi.org\/10.1182\/blood-2022-157210.","journal-title":"Blood"},{"issue":"17","key":"1318_CR48","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845\u201357. https:\/\/doi.org\/10.1182\/blood.2021014586.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1318_CR49","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1182\/blood-2025-654","volume":"146","author":"J Altman","year":"2025","unstructured":"Altman J, Perl A, Wang E, et al. Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy (chemo): interim results from the phase 1\/2 VICEROY study. Blood. 2025;146(Suppl. 1):654. https:\/\/doi.org\/10.1182\/blood-2025-654.","journal-title":"Blood"},{"issue":"7","key":"1318_CR50","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1158\/1078-0432.CCR-23-2234","volume":"30","author":"A Woods","year":"2024","unstructured":"Woods A, Norsworthy KJ, Wang X, et al. FDA approval summary: ivosidenib in combination with azacitidine for treatment of patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. Clin Cancer Res. 2024;30(7):1226\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2234.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1318_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100152","volume":"2","author":"CA Lachowiez","year":"2025","unstructured":"Lachowiez CA, Smith BD, Ambinder AJ, et al. Ivosidenib or venetoclax combined with hypomethylating agents in IDH1-mutated acute myeloid leukemia: a real-world study. Blood Neoplasia. 2025;2(4):100152. https:\/\/doi.org\/10.1016\/j.bneo.2025.100152.","journal-title":"Blood Neoplasia"},{"issue":"1","key":"1318_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00604-2","volume":"12","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, Takahashi K, Daver N, et al. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022;12(1):10. https:\/\/doi.org\/10.1038\/s41408-021-00604-2.","journal-title":"Blood Cancer J"},{"issue":"24","key":"1318_CR53","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO-25-00640","volume":"43","author":"CD DiNardo","year":"2025","unstructured":"DiNardo CD, Marvin-Peek J, Loghavi S, et al. Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy-ineligible patients with isocitrate dehydrogenas-mutated AML. J Clin Oncol. 2025;43(24):2692\u20139. https:\/\/doi.org\/10.1200\/JCO-25-00640.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1318_CR54","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1716984.","journal-title":"N Engl J Med"},{"issue":"6","key":"1318_CR55","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722\u201331. https:\/\/doi.org\/10.1182\/blood-2017-04-779405.","journal-title":"Blood"},{"issue":"9","key":"1318_CR56","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1182\/blood.2025028357","volume":"146","author":"ML Arellano","year":"2025","unstructured":"Arellano ML, Thirman MJ, DiPersio JF, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025;146(9):1065\u201377. https:\/\/doi.org\/10.1182\/blood.2025028357.","journal-title":"Blood"},{"issue":"1","key":"1318_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43(1):75\u201384. https:\/\/doi.org\/10.1200\/JCO.24.00826.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1318_CR58","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO-25-01694","volume":"43","author":"ES Wang","year":"2025","unstructured":"Wang ES, Montesinos P, Foran J, et al. Ziftomenib in relapsed or refractory NPM1-mutated AML. J Clin Oncol. 2025;43(31):3381\u201390. https:\/\/doi.org\/10.1200\/JCO-25-01694.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"1318_CR59","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2025-763","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Zeidner J, Watts J, et al. Monotherapy update from phase 1 portion in phase1\/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2025;146(Suppl. 1):763. https:\/\/doi.org\/10.1182\/blood-2025-763.","journal-title":"Blood"},{"issue":"23","key":"1318_CR60","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1200\/JCO-25-00914","volume":"43","author":"JF Zeidner","year":"2025","unstructured":"Zeidner JF, Lin TL, Welkie RL, et al. Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML. J Clin Oncol. 2025;43(23):2606\u201315. https:\/\/doi.org\/10.1200\/JCO-25-00914.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"1318_CR61","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2025-766","volume":"146","author":"G Roboz","year":"2025","unstructured":"Roboz G, Wang E, Fathi A, et al. Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: phase 1b results from KOMET-007. Blood. 2025;146(Suppl. 1):766. https:\/\/doi.org\/10.1182\/blood-2025-766.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1318_CR62","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2025-764","volume":"146","author":"G Issa","year":"2025","unstructured":"Issa G, Fathi A, Zeidan A, et al. Ziftomenib in combination with venetoclax and azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: updated phase 1a\/b safety and clinical activity results from KOMET-007. Blood. 2025;146(Suppl. 1):764. https:\/\/doi.org\/10.1182\/blood-2025-764.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1318_CR63","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1182\/blood-2025-3429","volume":"146","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Sallman D, Briseno-Toomey D, et al. Camelot-2: a phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed acute myeloid leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy. Blood. 2025;146(Suppl. 1):3429. https:\/\/doi.org\/10.1182\/blood-2025-3429.","journal-title":"Blood"},{"issue":"2","key":"1318_CR64","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40487-022-00200-9","volume":"10","author":"TW LeBlanc","year":"2022","unstructured":"LeBlanc TW, Russell NH, Hernandez-Aldama L, et al. Patient, family member and physician perspectives and experiences with AML treatment decision-making. Oncol Ther. 2022;10(2):421\u201340. https:\/\/doi.org\/10.1007\/s40487-022-00200-9.","journal-title":"Oncol Ther"},{"issue":"16_Suppl.","key":"1318_CR65","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1200\/JCO.2025.43.16_suppl.1537","volume":"43","author":"KP Loh","year":"2025","unstructured":"Loh KP. Trade-off preferences in older adults with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2025;43(16_Suppl.):1537. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.1537.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1318_CR66","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1158\/1055-9965.EPI-19-1277","volume":"29","author":"DR Richardson","year":"2020","unstructured":"Richardson DR, Crossnohere NL, Seo J, et al. Age at diagnosis and patient preferences for treatment outcomes in AML: a discrete choice experiment to explore meaningful benefits. Cancer Epidemiol Biomarkers Prev. 2020;29(5):942\u20138. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-1277.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"1318_CR67","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"key":"1318_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2024.100453","volume":"21","author":"M Martelli","year":"2024","unstructured":"Martelli M, Di Renzo N, Curti A, et al. Real-world treatments and clinical outcomes in unfit AML patients receiving first-line treatment or best supportive care in Italy (CURRENT study). Leuk Res Rep. 2024;21:100453. https:\/\/doi.org\/10.1016\/j.lrr.2024.100453.","journal-title":"Leuk Res Rep."},{"issue":"6","key":"1318_CR69","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ejh.13753","volume":"108","author":"C Papayannidis","year":"2022","unstructured":"Papayannidis C, Nanni J, Cristiano G, et al. Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents. Eur J Haematol. 2022;108(6):449\u201359. https:\/\/doi.org\/10.1111\/ejh.13753.","journal-title":"Eur J Haematol"},{"issue":"7","key":"1318_CR70","doi-asserted-by":"publisher","first-page":"8581","DOI":"10.1002\/cam4.5547","volume":"12","author":"M LoCastro","year":"2023","unstructured":"LoCastro M, Sanapala C, Wang Y, et al. Patient-centered communication tool for older patients with acute myeloid leukemia, their caregivers, and oncologists: a single-arm pilot study. Cancer Med. 2023;12(7):8581\u201393. https:\/\/doi.org\/10.1002\/cam4.5547.","journal-title":"Cancer Med"},{"issue":"2","key":"1318_CR71","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/10428194.2020.1832662","volume":"62","author":"KP Loh","year":"2021","unstructured":"Loh KP, Abdallah M, Kadambi S, et al. Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists. Leuk Lymphoma. 2021;62(2):387\u201398. https:\/\/doi.org\/10.1080\/10428194.2020.1832662.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"1318_CR72","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1182\/bloodadvances.2021005845","volume":"6","author":"HL Amonoo","year":"2022","unstructured":"Amonoo HL, Bodd MH, Reynolds MJ, et al. Coping strategies in patients with acute myeloid leukemia. Blood Adv. 2022;6(7):2435\u201342. https:\/\/doi.org\/10.1182\/bloodadvances.2021005845.","journal-title":"Blood Adv"},{"issue":"7","key":"1318_CR73","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1182\/blood-2018-03-842575","volume":"132","author":"TW LeBlanc","year":"2018","unstructured":"LeBlanc TW, Egan PC, Olszewski AJ. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. Blood. 2018;132(7):717\u201326. https:\/\/doi.org\/10.1182\/blood-2018-03-842575.","journal-title":"Blood"},{"key":"1318_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1642472","volume":"15","author":"F Ferrara","year":"2025","unstructured":"Ferrara F, Geissler K, Mehta P, Montesinos P, Venditti A. Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel. Front Oncol. 2025;15:1642472. https:\/\/doi.org\/10.3389\/fonc.2025.1642472.","journal-title":"Front Oncol"},{"issue":"2","key":"1318_CR75","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamaoncol.2020.6343","volume":"7","author":"A El-Jawahri","year":"2021","unstructured":"El-Jawahri A, LeBlanc TW, Kavanaugh A, et al. Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: a randomized clinical trial. JAMA Oncol. 2021;7(2):238\u201345. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6343.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1318_CR76","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ejon.2014.05.006","volume":"18","author":"A Velghe","year":"2014","unstructured":"Velghe A, Petrovic M, De Buyser S, Demuynck R, Noens L. Validation of the G8 screening tool in older patients with aggressive haematological malignancies. Eur J Oncol Nurs. 2014;18(6):645\u20138. https:\/\/doi.org\/10.1016\/j.ejon.2014.05.006.","journal-title":"Eur J Oncol Nurs"},{"issue":"6","key":"1318_CR77","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00277-013-2001-0","volume":"93","author":"ME Hamaker","year":"2014","unstructured":"Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol. 2014;93(6):1031\u201340. https:\/\/doi.org\/10.1007\/s00277-013-2001-0.","journal-title":"Ann Hematol"},{"key":"1318_CR78","unstructured":"National Comprehensive Cancer Network. Older adult oncology (Version 2.2025). 13 May 2025. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=4&id=1452. [Accessed 28 Jun 2026]."},{"key":"1318_CR79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e23222","volume":"42","author":"J Schmoyer","year":"2024","unstructured":"Schmoyer J, Hadjis A, White G, Lai C, McCurdy S. Association of Fried\u2019s frailty phenotype, but not the clinical frailty scale, with overall survival in older adults with acute myeloid leukemia. J Clin Oncol. 2024;42:e23222. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e23222.","journal-title":"J Clin Oncol"},{"key":"1318_CR80","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejca.2017.06.027","volume":"83","author":"C Martinez-Tapia","year":"2017","unstructured":"Martinez-Tapia C, Paillaud E, Liuu E, et al. Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer. Eur J Cancer. 2017;83:211\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2017.06.027.","journal-title":"Eur J Cancer"},{"issue":"10","key":"1318_CR81","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","volume":"29","author":"A Hurria","year":"2011","unstructured":"Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011;29(10):1290\u20136. https:\/\/doi.org\/10.1200\/JCO.2010.30.6985.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1318_CR82","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","volume":"105","author":"ERM Scheepers","year":"2020","unstructured":"Scheepers ERM, Vondeling AM, Thielen N, van der Griend R, Stauder R, Hamaker ME. Geriatric assessment in older patients with a hematologic malignancy: a systematic review. Haematologica. 2020;105(6):1484\u201393. https:\/\/doi.org\/10.3324\/haematol.2019.245803.","journal-title":"Haematologica"},{"issue":"2","key":"1318_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101626","volume":"15","author":"M Extermann","year":"2024","unstructured":"Extermann M, Artz A, Rebollo MA, et al. Treating acute myelogenous leukemia in patients aged 70 and above: recommendations from the International Society of Geriatric Oncology (SIOG). J Geriatr Oncol. 2024;15(2):101626. https:\/\/doi.org\/10.1016\/j.jgo.2023.101626.","journal-title":"J Geriatr Oncol."},{"issue":"16_Suppl.","key":"1318_CR84","doi-asserted-by":"publisher","first-page":"12040","DOI":"10.1200\/JCO.2022.40.16_suppl.12040","volume":"40","author":"C Lai","year":"2022","unstructured":"Lai C, Conway O, Lee M, Le-Rademacher J, Mandelblatt JS, Klepin HD. Deficit accumulation frailty index (DAFI) scores and acute myeloid leukemia outcomes. J Clin Oncol. 2022;40(16_Suppl.):12040. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.12040.","journal-title":"J Clin Oncol"},{"key":"1318_CR85","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.2147\/PPA.S421871","volume":"17","author":"L Saini","year":"2023","unstructured":"Saini L, Griffin J, Pandya B, et al. Patient and physician preferences for acute myeloid leukemia maintenance treatments following hematopoietic stem cell transplantation. Patient Prefer Adherence. 2023;17:2805\u201319. https:\/\/doi.org\/10.2147\/PPA.S421871.","journal-title":"Patient Prefer Adherence"},{"key":"1318_CR86","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2147\/PPA.S442530","volume":"18","author":"DJ Mott","year":"2024","unstructured":"Mott DJ, Hitch J, Nier S, Pemberton-Whiteley Z, Skedgel C. Patient preferences for treatment in relapsed\/refractory acute leukemia in the United Kingdom: a discrete choice experiment. Patient Prefer Adherence. 2024;18:1243\u201355. https:\/\/doi.org\/10.2147\/PPA.S442530.","journal-title":"Patient Prefer Adherence"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01318-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01318-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01318-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:22:33Z","timestamp":1785518553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01318-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01318-5","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No external funding was used in the preparation of this article.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stephanie Franco, Christopher Wanjiku, and Daniel R. Richardson have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","label":"Conflicts of Interest\/Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SF performed the literature review, manuscript writing, generation of figures, and incorporation of revisions. CW performed the literature review, manuscript writing, generation of tables, and incorporation of revisions. DR provided expert oversight, manuscript writing, and incorporation of revisions.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}